BECAUTSE OF the neurotoxic side-effects of the drugs currently available clinically to sensitize hypoxic cells, it may be necessary to restrict drug administration to a few of the fractions in a course of radiotherapy. The question immediately arises as to whether it would be better to use the sensitizer early in the treatment course, at the end, or evenly spaced throughout. We believe that it would be best to use the drug at the beginning, for the reasons outlined below:
If a tumour were completely hypoxic and remained so throughout treatment the sensitizer would be equally effective regardless of when it was used. Similarly, if the tumour contained a proportion of hypoxic cells e.g. 10-20%, and these cells did not change their oxygen status as therapy progressed (i.e. no reoxygenation) the sensitizer would be equally effective with any fraction. This is illustrated schematically in Fig. 1 Although the surviving number of hypoxic cells is the same, 2a, regardless of whether the sensitizer is used with the first 4 or the last 4 of 8 fractions, the number of oxic cells produced by reoxygenation and hence the total number of cells surviving, 2c, is not the same. In Fig. 2 a uniform rate or reoxygenation has been assumed, with 20% of the hypoxic survivors at the end of each fraction being reoxygenated before the next dose. The same result is seen however, for a non-uniform rate of reoxygenation, for example reoxygenation occurring during the later fractions, perhaps when the tumour has started to shrink (Fig. 3) .
In these examples, using only 8 small daily fractions of 300 rad, half with reoxygenation occurs, moreover, there is no disadvantage in using the sensitizer at this time. The only situation where this rationale will not apply is if the tumour continues to grow during therapy, so that the number of hypoxic cells increases after the first fraction. This is obviously a hopeless situation anyway. There may be two other advantages of giving the sensitizer early. The use of misonidazole as a radiosensitizer sometimes causes more rapid shrinkage of mouse tumours (for the same amount of growth delay) than is seen with X-rays alone (Denekamp, unpublished) . Rapid tumour shrinkage may itself lead to more effective reoxygenation, which would render the tumour more sensitive to the subsequent X-ray doses (Dische, 1974; Denekamp, 1977) . Secondly, if direct cytotoxicity to hypoxic cells is an important component of the effect of nitroimidazoles, early administration of the drug would expose the maximum number of hypoxic cells in the primary tumour to its cytotoxic action, together with any hypoxic foci in distant metastases at the earliest possible phase of their growth.
In summary, the use of a hypoxic cell sensitizer at the start of therapy will be an advantage in any tumour which reoxygenates, and will be no disadvantage in a tumour which does not. This rationale will apply equally to any method designed to kill hypoxic cells specifically, including the electron-affinic radiosensitizers, high LET radiation or hyperbaric oxygen.
